UBS Group AG - IMMUNOVANT INC ownership

IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 97 filers reported holding IMMUNOVANT INC in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.

Quarter-by-quarter ownership
UBS Group AG ownership history of IMMUNOVANT INC
ValueSharesWeighting
Q3 2023$3,255,356
+86.7%
84,797
-7.8%
0.00%0.0%
Q2 2023$1,744,006
-8.6%
91,935
-25.3%
0.00%0.0%
Q1 2023$1,908,289
-30.1%
123,036
-20.0%
0.00%0.0%
Q4 2022$2,731,281
+6903.3%
153,875
+2105.1%
0.00%
Q3 2022$39,000
+333.3%
6,978
+205.7%
0.00%
Q2 2022$9,000
-99.4%
2,283
-98.6%
0.00%
Q4 2021$1,418,000
+235.2%
166,534
+241.7%
0.00%
Q3 2021$423,000
+9.3%
48,738
+33.0%
0.00%
Q2 2021$387,000
-71.0%
36,643
-55.9%
0.00%
Q1 2021$1,333,000
-41.4%
83,130
+68.8%
0.00%
-100.0%
Q4 2020$2,274,000
+7480.0%
49,235
+5768.3%
0.00%
Q3 2020$30,000
-82.2%
839
-87.9%
0.00%
Q2 2020$169,000
+356.8%
6,955
+195.1%
0.00%
Q1 2020$37,000
+117.6%
2,357
+119.1%
0.00%
Q4 2019$17,0001,0760.00%
Other shareholders
IMMUNOVANT INC shareholders Q2 2022
NameSharesValueWeighting ↓
Alpine Global Management, LLC 4,448,017$17,347,0004.39%
Deep Track Capital, LP 9,455,000$36,875,0002.42%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 233$60,000,0000.63%
Octagon Capital Advisors LP 579,061$2,258,0000.60%
Eventide Asset Management 5,372,512$20,953,0000.45%
WITTENBERG INVESTMENT MANAGEMENT, INC. 174,000$679,0000.29%
Frazier Life Sciences Management, L.P. 585,759$2,284,0000.22%
BCK CAPITAL MANAGEMENT LP 54,293$212,0000.16%
PLATINUM INVESTMENT MANAGEMENT LTD 777,590$3,033,0000.12%
Bridgefront Capital, LLC 15,649$61,0000.07%
View complete list of IMMUNOVANT INC shareholders